Ozempic manufacturing costs could be 89c per month, study finds

Novo Nordisk’s (LLY) Ozempic could be manufactured for 89c to $4.73 for one month’s supply, according to an investigation published in JAMA Network Open. The study asks what prices of insulins, sodium-glucose cotransporter inhibitors and glucagonlike peptide 1 agonists could be if they were closer to the cost of production. “High prices limit access to newer diabetes medicines in many countries. The findings of this study suggest that robust generic and biosimilar competition could reduce prices to more affordable levels and enable expansion of diabetes treatment globally,” the paper states. The study argues that prices could decrease to $1.30 per month for treatment with SGLT2Is and under 75c for treatment with GLP1As. Further price reductions will likely become possible once a robust global generic and biosimilar market emerges, it adds.